Leerink Partnrs Issues Pessimistic Outlook for ALDX Earnings

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) – Equities research analysts at Leerink Partnrs lowered their FY2028 earnings per share (EPS) estimates for shares of Aldeyra Therapeutics in a research note issued to investors on Wednesday, November 13th. Leerink Partnrs analyst M. Goodman now expects that the biotechnology company will earn $2.50 per share for the year, down from their previous forecast of $2.55. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.48) per share.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.25).

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Aldeyra Therapeutics in a report on Friday, August 9th.

Aldeyra Therapeutics Trading Down 1.4 %

Shares of NASDAQ:ALDX opened at $4.21 on Friday. The company has a 50-day moving average price of $5.45 and a 200 day moving average price of $4.60. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.18. Aldeyra Therapeutics has a 12 month low of $2.43 and a 12 month high of $6.55.

Institutional Trading of Aldeyra Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. King Wealth Management Group boosted its stake in shares of Aldeyra Therapeutics by 24.5% during the third quarter. King Wealth Management Group now owns 13,700 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 2,700 shares during the period. The Manufacturers Life Insurance Company boosted its position in Aldeyra Therapeutics by 14.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,734 shares of the biotechnology company’s stock valued at $72,000 after buying an additional 2,729 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Aldeyra Therapeutics by 7.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 48,273 shares of the biotechnology company’s stock worth $158,000 after acquiring an additional 3,446 shares in the last quarter. Providence Wealth Advisors LLC increased its position in shares of Aldeyra Therapeutics by 16.3% during the second quarter. Providence Wealth Advisors LLC now owns 25,000 shares of the biotechnology company’s stock worth $84,000 after acquiring an additional 3,500 shares during the period. Finally, Laidlaw Wealth Management LLC increased its position in shares of Aldeyra Therapeutics by 32.6% during the second quarter. Laidlaw Wealth Management LLC now owns 16,875 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 4,150 shares during the period. 59.71% of the stock is owned by hedge funds and other institutional investors.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.